Researchers at the University of California, Los Angeles (UCLA), in collaboration with pathologists from Hadassah Hebrew ...
Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...
Introduction: Since the release of the World Health Organization (WHO) Classification of Tumours-Digestive System Tumours in 2019, the pathology of intrahepatic cholangiocarcinoma (iCCA) has entered ...
Digital Pathology: The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis, as the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...
Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could become ...
The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...
Background and aims: Multiplex immunohistochemistry/immunofluorescence (mIHC/IF), which uses the tyramide signal amplification (TSA) technique, enables sequential ...
Immunohistochemistry (IHC) is an essential tool in oncology, enabling pathologists to detect and quantify protein expression which in turn guides decisions for systemic therapy. However, while several ...
The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback